vTv Therapeutics begins randomisation in Phase 3 cadisegliatin trial for type 1 diabetes
Cadisegliatin, or TTP399, is a liver-selective glucokinase activator with FDA breakthrough therapy designation.
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery